Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
Complex Lesion Subsets: Indications for DES Andreas Baumbach, MD, FRCP, FESC Bristol Heart Institute.
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
IVUS Use during Left Main PCI improve Immediate and Long Term Outcome Where is the Evidence? E Murat Tuzcu, MD, FACC Professor of Medicine Vice Chairman.
Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
APPOSITION II study results Robert-Jan van Geuns, MD On behalf of the APPOSITION II Investigators.
Dr. V.K.AJIT KUMAR PROFESSOR, DEPT. of CARDIOLOGY, SCTIMST, TRIVANDRUM STENT CHOICE IN AMI.
Can IVUS Define Plaque Features that Impact Patient Care? A Pichard L Satler, K Kent, R Waksman, W Suddath, N Bernardo, N Weissman, M Angelo, D Harrington,
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Trials of radiation to prevent or reduce in-stent restenosis Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director.
Elective Stenting versus Balloon Angioplasty with Bail-out Stenting for Small Vessel Coronary Artery Disease: Evidence from a Meta-analysis of Randomized.
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
When I Use IVUS Neal Uren MD FRCP Consultant Cardiologist Royal Infirmary Edinburgh.
Unresolved issues with Drug-eluting Stents Stent Thrombosis Advanced Angioplasty 2007 Dan Blackman Yorkshire Heart Centre.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Maurizio Menichelli MD San Camillo Hospital, Rome ( SESAMI Trial) Maurizio Menichelli Presenter Disclosure Information Nothing to Disclose Randomized trial.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Which is the role of post-dilation after DES implantation? Enrico Romagnoli 1,2 M.D., Ph.D. 1 Policlinico Casilino, Roma 2 Opedale San Raffaele, Milano.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Late loss in the choice of DES: Monty Python or the Holy Grail? Azfar Zaman Freeman Hospital, Newcastle-upon-Tyne.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Follow-up Clinico e Trattamento Post- Rivascolarizzazione Percutanea Giuseppe Biondi Zoccai University of Turin, Turin, Italy Marrakesh,
Saqib Chowdhary Wythenshawe Hospital STENT THROMBOSIS How Do IVUS & OCT Help.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
UpdateDEB Lesions Learned from the Trials and Daily Clinical Practice Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
D.DELEANU, M.CROITORU BUCHAREST, ROMANIA. BTK Interventions ? BTK disease = claudication and CLI BTK interventions = CLI Main goal of CLI therapy = functional.
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
DES In-Stent Restenosis:
DCB for In-Stent Restenosis: Is It Superior to DES?
Clinical Usefulness of Post-Stenting FFR
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
Drug Eluting Balloons Bodo Cremers, MD
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
DES Should be Used as the Default Stent in ACS!
OCT-Guided PCI What needs to be done to establish criteria?
Stenting of Coronary Arteries in Non Stress/Benestent Disease
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
Angiography-guided PCI
American College of Cardiology Presented by Dr. Stephan Windecker
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
REALITY: 8 month results
Presented at ACC 2003 Late Breaking Clinical Trials
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bernardo Cortese, MD Ospedale della Misericordia Grosseto Italy
(p < 0.05 for paclitaxel angioplasty vs. either control)
Drug-eluting stents for in-stent restenosis
ENDEAVOR II Five-Year Clinical Follow-up
Maintenance of Long-Term Clinical Benefit with
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts, S. Epstein, N. Weissman, A. Fuisz, G. Weigold, J. Lindsay Augusto Pichard, MD PCI in Small Vessels: A Comprehensive Approach

Technical approach PCI in Small Vessels Definition A true small vessel: A Vessel that Perfuses Small Amount of Myocardium

Technical approach PCI in Small Vessels First Conclusion: True small vessels do not need PCI Conclusion (1)

Technical approach PCI in Small Vessels Is this proximal LAD a small vessel ? No a large vessel with diffuse disease IVUS: 4 mm Insights From IVUS

Technical approach PCI in Small Vessels Patient Referred for ISRS of a 2.5 mm stent in the LAD. Vessel size ? RAO cranial IVUS 4 mm 2.5 mm Insights From IVUS

Technical approach PCI in Small Vessels Insights From IVUS WHC IVUS Core Lab Laborgne, Cheneau et al LAD size assessment by IVUS

Technical approach PCI in Small Vessels Vessel size: Angiography vs IVUS Insights From IVUS

Technical approach PCI in Small Vessels Second Conclusion: The proximal LAD is almost never a small vessel. (The same is often true for the proximal RCA and CX). Conclusion (2)

Technical approach PCI in Small Vessels PCI of Small Vessels Which one is the best tool ? 1. Balloon? 2. Cutting Balloon ? 3. Stent ? 4. Specialized Stents (PC coating, Pixel, Silicon Carbide coating, etc.)? 5. Drug eluting stents ? Materials

Technical approach PCI in Small Vessels PCI of Small Vessels Stents

Technical approach PCI in Small Vessels Stent vs. Balloon in Small Vessels Kastrati et al. JACC 38:1604 Final Diameter Stenosis in the Balloon Arm Percent Difference in Restenosis between Balloon and Stent Stent vs Balloon

Technical approach PCI in Small Vessels Provisional Stenting in Vessels <2.7 mm WHC: Abizaid, Pichard et al. ACC lesions with provisional stenting under IVUS guidance. 45% crossed-over to stent. 453 control lesions with elective stenting. Results

Technical approach PCI in Small Vessels Why are Stents Less Effective in Small Vessels ? IVUS Core LAB. Washington Hospital Center ISRS is highest in small vessels Small vessels develop the same amount of intimal hyperplasia as large vessels WHC: Mintz et al. 1997WHC: Hoffmann AJC 1998;82: Limitations

Technical approach PCI in Small Vessels Mean IH thickness vs Stent CSA at 6-month follow up in N on-Polymeric Paclitaxel-coated Stents. Mintz et al. TCT 2003 Control High dose Low dose Per slice bases R=0.009 P=0.87 R=0.126 P=0.01 R=0.002 P=0.96 Stent CSA (mm²) DES

Technical approach PCI in Small Vessels Small Vessel PCI Any benefit with specialized approach ? Rotablator Cutting balloon Special coatings Specialized Approach

Technical approach PCI in Small Vessels Rotablator vs. Balloon for Small Vessels. DART Trial. Mauri et al. AHJ 2003; 145: patients randomized Vessel diameter (mean 2.46). Lesion length: 10±6 mm. Procedural success: 92% (R) vs 94% (B). 12 months follow up: – angio restenosis: 50.5% in both. – late loss: 0.49 (R) vs 0.56 (B). Conclusion: no benefit of Rotablator in Small Vessels Rotablator

Technical approach PCI in Small Vessels Cutting Balloon vs. Balloon in Small Vessels Cutting balloon

Technical approach PCI in Small Vessels Cutting Balloon vs. Stent in Small Vessels Refer. Vess. Diam: 2.2 mm 2.3 mm 2.2 mm 2.4 mm n= 86 pts. 310 lesions 48 pts. 174 pts. 1: Kawaguchi. JACC 2002;39:48a; 2: Kawaguchi JACC 2002;39:7A; 3: Kinoshita AJC 2003; 92:170L; 4:Umeda JACC 2002;39:52 A Cutting balloon

Technical approach PCI in Small Vessels TENAX Stent (Silicon Carbide Coated Stent). SVS Trial (Small Vessel Study). Bonnier et al. CRT patients with Small Vessels ( mm) randomized SiC coating

Technical approach PCI in Small Vessels Heparin-Coated Stent in Small Vessels. COAST Trial. Haude et al. Circulation. 2003;107: Restenosis: 32.2% after PTCA with provisional stenting, 24.8% after bare stenting, and 29.6% after heparin-coated stenting. (P=0.34). 588 pts. randomized to angioplasty with provisional stent (n=195), bare stenting (n=196), or Corline heparin-coated stenting (n=197). (JomedFlex Stent) Heparin

Technical approach PCI in Small Vessels BiodivYsio PC Coating Stent in Small Vessels. Lasmal Trial. Rodriguez et al. Buenos Aires PC Coating

Technical approach PCI in Small Vessels ISAR SMART-II: Randomized vessels <2.5 mm BiodivYsio PC Coating Kastrati; TCT 2003 PC Coating

Technical approach PCI in Small Vessels Third conclusion Bare metal stents have the same restenosis rate as optimal balloon angioplasty. Cutting balloon seems to offer a restenosis benefit in small vessels. Stents with special coatings offer no detectable advantage. Conclusion (3)

Technical approach PCI in Small Vessels ISAR SMART-II: Randomized vessels <2.5 mm Abciximab Anti- GPIIb/IIIa

Technical approach PCI in Small Vessels Restenosis with Cilostazol in PCI. CREST Trial Diabetic restenosis p= Small vessel restenosis p= Diabetics >2.75mm p=ns Diabetics <2.75mm p=ns CP CPCPCP C=Cilostazol P=Placebo Devireddy. Circulation 2004;110:III-489 Drug

Technical approach PCI in Small Vessels Drug Eluting Stents in Small Vessels

Technical approach PCI in Small Vessels DES vs BMS in Small Vessels. Randomized Trials % RS DES

Technical approach PCI in Small Vessels Late Loss in Small Vessels. BMS vs DES Randomized Trials mm DES

Technical approach PCI in Small Vessels Oct 04 DES Diameters

Technical approach PCI in Small Vessels SES diameters used (n=16251) 30% SES Diameters

Technical approach PCI in Small Vessels Fourth conclusion Drug Eluting Stent is clearly the device of choice for small vessels. Conclusion (4)

Technical approach PCI in Small Vessels Is the “Bigger is Better” Stent Strategy Necessary when Stenting Small Vessels?

Technical approach PCI in Small Vessels MACE in Small Vessels and Stent Lumen Area Iakovou et al. AJC 2003;92: pts with 446 stents in vessels <2.75mm. Group 1: 308 pts with final CSA <6 mm2. Group 2: 115 pts with final CSA > 6mm2. 1 year f/u IVUS

Technical approach PCI in Small Vessels How Big is Better in Small Vessels ? Moussa et al. AJC 1999;83: IVUS

Technical approach PCI in Small Vessels Final Stent Area and Restenosis. SIRIUS IVUS sub study. 72 SES and 50 BMS. Sonoda, et al. JACC 2004;43: Drug Eluting Stents IVUS

Technical approach PCI in Small Vessels Final Stent Area and Follow up Lumen Area SIRIUS IVUS sub study. 72 SES and 50 BMS. Sonoda, et al. JACC 2004;43: IVUS

Technical approach PCI in Small Vessels Stent area and Outcome at 6 months N=209 patients, N= 319 lesions treated with Cypher TLR MACE P=0.068P= % 0% 4.4% 2.2% % <66-7.5>7.5<66-7.5>7.5 Minimal stent CSA (mm 2 ) by Ivus Follow up

Technical approach PCI in Small Vessels IVUS Findings in SAT. Cheneau et al. Circulation. 2003;108: PCI’s with IVUS: 27 SAT (0.36%) Inadequate Stent Expansion 18 (78%) Stent malappostition 2 (5%) Dissection 4 (17%) Tissue protrusion 1 (4%) Thrombus post PCI 1 (4%) IVUS

Technical approach PCI in Small Vessels Summary 1.True small vessels do not need PCI. 2.The proximal LAD is almost never a small vessel. 3.Bare metal stent has same restenosis as optimal balloon angioplasty. Cutting balloon seems to offer a restenosis benefit. 4.Drug Eluting Stent is the device of choice for small vessels. 5.Adequate expansion in DES seems important (final stent area >6 mm2). Summary